Oncolytic Viral Therapy Using Reovirus

  • Chandini Thirukkumaran
  • Don G. MorrisEmail author
Part of the Methods in Molecular Biology™ book series (MIMB, volume 542)


Current mainstays in cancer treatment such as chemotherapy, radiation therapy, hormonal manipulation, and even targeted therapies such as trastuzumab (Herceptin) for breast cancer or erlotinib (Tarceva) for non-small cell lung cancer are limited by lack of efficacy, cellular resistance, and toxicity. Dose escalation and combination therapies designed to overcome resistance and increase efficacy are limited by a narrow therapeutic index. Oncolytic viruses are one such group of new biological therapeutics that appears to have a wide spectrum of anticancer activity with minimal human toxicity.

Because the malignant phenotype of tumours is the culmination of multiple mutations that occur in several genes eventually leading to aberrant signalling pathways, oncolytic viruses, either natural or engineered, specifically target tumour cells, taking advantage of this cellular deviant signalling for their replication. Reovirus is one such naturally occurring double-stranded RNA (dsRNA) virus that exploits altered Ras signalling pathways in a myriad of cancers. The ability of reovirus to infect and lyse tumours both solid and haematological, under in vitro, in vivo, and ex vivo conditions, is discussed in this chapter. The major mechanism of reovirus oncolysis of cancer cells has been shown to occur through apoptosis. In addition, the synergistic anti-tumour effects of reovirus in combination with radiation or chemotherapy has also been demonstrated for reovirus-resistant and moderately sensitive tumours. In most of the clinical trials undertaken to date, an anti-reovirus immune response has been seen likely circumventing efficacy. Investigation into the use of reovirus as an immune adjuvant is currently underway to try and re-direct this immune response to the tumour. Reovirus phase I clinical trials have shown indications of efficacy and several phase I/II trials are ongoing at present. The extensive pre-clinical efficacy, replication competency, and low toxicity profile in humans has placed the reovirus as an attractive anti-cancer therapeutic for ongoing clinical testing.

Key Words

Cancer clinical trials oncolytic viruses reovirus 


  1. 1.
    Butel JS. (2000) Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. Carcinogenesis; 21:405–426.PubMedCrossRefGoogle Scholar
  2. 2.
    DePace N. (1921) Sulla comparsa di un enorme cancro vegetante del collo dell'utero senza cura chirurgica. Ginecologia; 9:82–89.Google Scholar
  3. 3.
    Bluming AZ, Ziegler JL. (1971) Regression of Burkitt's lymphoma in association with measles infection. Lancet; 2:105–106.PubMedCrossRefGoogle Scholar
  4. 4.
    Taqi AM, Abdurrahman MB, Yakubu AM, Fleming AF. (1981) Regression of Hodgkin's disease after measles. Lancet; 1:1112.PubMedCrossRefGoogle Scholar
  5. 5.
    Moore AE. (1954) Effects of viruses on tumors. Annu Rev Microbiol; 8:393–410.PubMedCrossRefGoogle Scholar
  6. 6.
    Sinkovics J, Horvath J. (1993) New developments in the virus therapy of cancer: a historical review. Intervirology; 36:193–214.PubMedGoogle Scholar
  7. 7.
    Nibert M, Shiff L. (2001) Reoviruses and their replication. In: Knipe DM, Howley PM, editors. Fields Virology. Philadelphia, PA: Lippincott-Raven.Google Scholar
  8. 8.
    Weiner HL, Fields BN. (1977) Neutralization of reovirus: the gene responsible for the neutralization antigen. J Exp Med; 146:1305–1310.PubMedCrossRefGoogle Scholar
  9. 9.
    Ramos-Alvarez M, Sabin AB. (1954) Characteristics of poliomyelitis and other enteric viruses recovered in tissue culture from healthy American children. Proc Soc Exp Biol Med; 87:655–661.PubMedGoogle Scholar
  10. 10.
    Sabin AB. (1959) Reoviruses. A new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described. Science; 130:1387–1389.Google Scholar
  11. 11.
    Rosen L. (1960) Serologic grouping of reoviruses by hemagglutination-inhibition. Am J Hyg; 71:242–249.PubMedGoogle Scholar
  12. 12.
    Rosen L, Hovis JF, Mastrota FM, Bell JA, Huebner RJ. (1960) Observations on a newly recognized virus (Abney) of the reovirus family. Am J Hyg; 71:258–265.PubMedGoogle Scholar
  13. 13.
    Cashdollar LW, Chmelo RA, Wiener JR, Joklik WK. (1985) Sequences of the S1 genes of the three serotypes of reovirus. Proc Natl Acad Sci USA; 82:24–28.PubMedCrossRefGoogle Scholar
  14. 14.
    Duncan R, Horne D, Cashdollar LW, Joklik WK, Lee PW. (1990) Identification of conserved domains in the cell attachment proteins of the three serotypes of reovirus. Virology; 174:399–409.PubMedCrossRefGoogle Scholar
  15. 15.
    Atwater JA, Munemitsu SM, Samuel CE. (1986) Biosynthesis of reovirus-specified polypeptides. Molecular cDNA cloning and nucleotide sequence of the reovirus serotype 1 Lang strain s4 mRNA which encodes the major capsid surface polypeptide sigma 3. Biochem Biophys Res Commun; 136:183–192.PubMedCrossRefGoogle Scholar
  16. 16.
    Tarlow O, McCorquodale JG, McCrae MA. (1988) Molecular cloning and sequencing of the gene (M2) encoding the major virion structural protein (mu 1-mu 1C) of serotypes 1 and 3 of mammalian reovirus. Virology; 164:141–146.PubMedCrossRefGoogle Scholar
  17. 17.
    Dermody TS, Schiff LA, Nibert ML, Coombs KM, Fields BN. (1991) The S2 gene nucleotide sequences of prototype strains of the three reovirus serotypes: characterization of reovirus core protein sigma 2. J Virol; 65:5721–5731.PubMedGoogle Scholar
  18. 18.
    Zou S, Brown EG. (1992) Nucleotide sequence comparison of the M1 genome segment of reovirus type 1 Lang and type 3 Dearing. Virus Res; 22:159–164.PubMedCrossRefGoogle Scholar
  19. 19.
    SRANLEY NF, DORMAN DC, PONSFORD J. (1953) Studies on the pathogenesis of a hitherto undescribed virus (hepato-encephalomyelitis) producing unusual symptoms in suckling mice. Aust J Exp Biol Med Sci; 31:147–159.CrossRefGoogle Scholar
  20. 20.
    Saito T, Shinozaki K, Matsunaga T. (2004) Lack of evidence for reovirus infection in tissues from patients with biliary atresia and congenital dilatation of the bile duct. J Hepatol; 40:203–211.PubMedCrossRefGoogle Scholar
  21. 21.
    Loken SD, Norman K, Hirasawa K, Nodwell M, Lester WM, Demetrick DJ. (2004) Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (dearing 3) as an anti-cancer biotherapeutic. Cancer Biol Ther; 3:734–738.PubMedCrossRefGoogle Scholar
  22. 22.
    Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PW. (2002) Oncolytic reovirus against ovarian and colon cancer. Cancer Res; 62:1696–1701.PubMedGoogle Scholar
  23. 23.
    Rosen L, Evans HE, Spickard A. (1963) Reovirus infections in human volunteers. Am J Hyg; 77:29–37.PubMedGoogle Scholar
  24. 24.
    Johansson PJ, Sveger T, Ahlfors K, Ekstrand J, Svensson L. (1996) Reovirus type 1 associated with meningitis. Scand J Infect Dis; 28:117–120.PubMedCrossRefGoogle Scholar
  25. 25.
    Joske RA, Keall DD, Leak PJ, Stanley NF, Walters MN. (1964) Hepatitis-encephalitis in humans with reovirus infection. Arch Intern Med; 113:811–816.PubMedCrossRefGoogle Scholar
  26. 26.
    Strong JE, Tang D, Lee PW. (1993) Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency. Virology; 197:405–411.PubMedCrossRefGoogle Scholar
  27. 27.
    Tang D, Strong JE, Lee PW. (1993) Recognition of the epidermal growth factor receptor by reovirus. Virology; 197:412–414.PubMedCrossRefGoogle Scholar
  28. 28.
    Strong JE, Lee PW. (1996) The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol; 70(1):612–616.PubMedGoogle Scholar
  29. 29.
    Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. (1998) Increasing complexity of Ras signaling. Oncogene; 17:1395–1413.PubMedCrossRefGoogle Scholar
  30. 30.
    Bianco R, Melisi D, Ciardiello F, Tortora G. (2006) Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer; 42:290–294.PubMedCrossRefGoogle Scholar
  31. 31.
    Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. (1998) The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J; 17:3351–3362.PubMedCrossRefGoogle Scholar
  32. 32.
    Mundschau LJ, Faller DV. (1992) Oncogenic ras induces an inhibitor of double-stranded RNA-dependent eukaryotic initiation factor 2 alpha-kinase activation. J Biol Chem; 267:23092–23098.PubMedGoogle Scholar
  33. 33.
    Mundschau LJ, Faller DV. (1994) Endogenous inhibitors of the dsRNA-dependent eIF-2 alpha protein kinase PKR in normal and ras-transformed cells. Biochimie; 76:792–800.PubMedCrossRefGoogle Scholar
  34. 34.
    Bischoff JR, Samuel CE. (1989) Mechanism of interferon action. Activation of the human P1/eIF-2 alpha protein kinase by individual reovirus s-class mRNAs: s1 mRNA is a potent activator relative to s4 mRNA. Virology; 172:106–115.PubMedCrossRefGoogle Scholar
  35. 35.
    Panniers R, Henshaw EC. (1983) A GDP/GTP exchange factor essential for eukaryotic initiation factor 2 cycling in Ehrlich ascites tumor cells and its regulation by eukaryotic initiation factor 2 phosphorylation. J Biol Chem; 258:7928–7934.PubMedGoogle Scholar
  36. 36.
    Norman KL, Hirasawa K, Yang AD, Shields MA, Lee PW. (2004) Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci U S A; 101:11099–11104.PubMedCrossRefGoogle Scholar
  37. 37.
    Hashiro G, Loh PC, Yau JT. (1977) The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol; 54:307–315.PubMedCrossRefGoogle Scholar
  38. 38.
    Duncan MR, Stanish SM, Cox DC. (1978) Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol; 28:444–449.PubMedGoogle Scholar
  39. 39.
    Coffey MC, Strong JE, Forsyth PA, Lee PW. (1998) Reovirus therapy of tumors with activated Ras pathway. Science; 282:1332–1334.PubMedCrossRefGoogle Scholar
  40. 40.
    Connolly JL, Rodgers SE, Clarke P. (2000) Reovirus-induced apoptosis requires activation of transcription factor NF-kappaB. J Virol; 74:2981–2989.PubMedCrossRefGoogle Scholar
  41. 41.
    Clarke P, Meintzer SM, Spalding AC, Johnson GL, Tyler KL. (2001) Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection. Oncogene; 20:6910–6919.PubMedCrossRefGoogle Scholar
  42. 42.
    Clarke P, Tyler KL. (2007) Down-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosis. Apoptosis; 12:211–223.PubMedCrossRefGoogle Scholar
  43. 43.
    Smakman N, van den Wollenberg DJ, Elias SG. (2006) KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res; 66:5403–5408.PubMedCrossRefGoogle Scholar
  44. 44.
    Thirukkumaran C, Shi ZH, Spurrell J, Thirukkumaran P, Morris D. (2007) Breast cancer oncolysis by reovirus is mediated through upregulation of PUMA and NF-kB proteins of the apoptotic signalling pathway [abstract]. In: Proceedings of the 98th Annual Meeting of the American Association for Cancer Research; AACR; 2007. 48. Abstract nr. 1929.Google Scholar
  45. 45.
    Thirukkumaran C, Thirukkumaran P, Morris D. (2005) Gene expression profiling of reovirus oncolysis in breast cancer [abstract]. In: Proceedings of the 96th Annual Meeting of the American Association for Cancer Research; AACR; 2005. 46. Abstract nr. 24.Google Scholar
  46. 46.
    Wilcox ME, Yang W, Senger D. (2001) Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst; 93:903–912.PubMedCrossRefGoogle Scholar
  47. 47.
    Norman KL, Coffey MC, Hirasawa K. (2002) Reovirus oncolysis of human breast cancer. Hum Gene Ther; 13:641–652.PubMedCrossRefGoogle Scholar
  48. 48.
    Kilani RT, Tamimi Y, Hanel EG. (2003) Selective reovirus killing of bladder cancer in a co-culture spheroid model. Virus Res; 93:1–12.PubMedCrossRefGoogle Scholar
  49. 49.
    Etoh T, Himeno Y, Matsumoto T. (2003) Oncolytic viral therapy for human pancreatic cancer cells by reovirus. Clin Cancer Res; 9:1218–1223.PubMedGoogle Scholar
  50. 50.
    Nodwell M, Thirukkumaran CM, Luider J et al. (2000) Reovirus as a novel prostate cancer therapeutic. American Association for Cancer Research (AACR) 91st annual meeting proceedings 41, Abstract nr. 122. 2000.Google Scholar
  51. 51.
    Alain T, Hirasawa K, Pon KJ. (2002) Reovirus therapy of lymphoid malignancies. Blood; 100:4146–4153.PubMedCrossRefGoogle Scholar
  52. 52.
    Thirukkumaran CM, Luider JM, Stewart DA. (2003) Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood; 102:377–387.PubMedCrossRefGoogle Scholar
  53. 53.
    Libermann TA, Nusbaum HR, Razon N. (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature; 313:144–147.PubMedCrossRefGoogle Scholar
  54. 54.
    Guha A, Dashner K, Black PM, Wagner JA, Stiles CD. (1995) Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer; 60:168–173.PubMedCrossRefGoogle Scholar
  55. 55.
    Yang WQ, Lun X, Palmer CA. (2004) Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin Cancer Res; 10:8561–8576.PubMedCrossRefGoogle Scholar
  56. 56.
    Forsyth P, Roldan G, George D et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 2008; 16(3):627–632.PubMedCrossRefGoogle Scholar
  57. 57.
    Rutka JT. (1997) Medulloblastoma. Clin Neurosurg; 44:571–585.PubMedGoogle Scholar
  58. 58.
    Yang WQ, Senger D, Muzik H. (2003) Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma. Cancer Res; 63:3162–3172.PubMedGoogle Scholar
  59. 59.
    Morris DG, Forsyth PA, Paterson AH et al. (2002) A phase 1 clinical trial evalutating entralesional REOLYSIN (reovirus) in histologically confirmed malignancies [abstract]. In: Proceedings of American Society of Clinical Oncology; ASCO; 2002. 21. p 24a. Abstract nr. 92.Google Scholar
  60. 60.
    Dankort DL, Wang Z, Blackmore V, Moran MF, Muller WJ. (1997) Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation. Mol Cell Biol; 17:5410–5425.PubMedGoogle Scholar
  61. 61.
    Slamon DJ, Godolphin W, Jones LA. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science; 244:707–712.PubMedCrossRefGoogle Scholar
  62. 62.
    deFazio A, Chiew YE, Sini RL, Janes PW, Sutherland RL. (2000) Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer; 87:487–498.PubMedCrossRefGoogle Scholar
  63. 63.
    Russello SV, Shore SK. (2003) Src in human carcinogenesis. Front Biosci; 8:1068–1073.CrossRefGoogle Scholar
  64. 64.
    Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ. (2000) Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res; 2:203–210.PubMedCrossRefGoogle Scholar
  65. 65.
    Prenzel N, Zwick E, Leserer M, Ullrich A. (2000) Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification. Breast Cancer Res; 2:184–190.PubMedCrossRefGoogle Scholar
  66. 66.
    Yang WQ, Senger DL, Lun XQ. (2004) Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer. Gene Ther; 11:1579–1589.PubMedCrossRefGoogle Scholar
  67. 67.
    Bos JL. (1989) ras oncogenes in human cancer: a review. Cancer Res; 49:4682–4689.PubMedGoogle Scholar
  68. 68.
    Smakman N, van der Bilt JD, van den Wollenberg DJ, Hoeben RC, Borel R, I, Kranenburg O. (2006) Immunosuppression promotes reovirus therapy of colorectal liver metastases. Cancer Gene Ther; 13:815–818.PubMedCrossRefGoogle Scholar
  69. 69.
    Hanel EG, Xiao Z, Wong KK, Lee PW, Britten RA, Moore RB. (2004) A novel intravesical therapy for superficial bladder cancer in an orthotopic model: oncolytic reovirus therapy. J Urol; 172:2018–2022.PubMedCrossRefGoogle Scholar
  70. 70.
    Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell; 53:549–554.PubMedCrossRefGoogle Scholar
  71. 71.
    Himeno Y, Etoh T, Matsumoto T, Ohta M, Nishizono A, Kitano S. (2005) Efficacy of oncolytic reovirus against liver metastasis from pancreatic cancer in immunocompetent models. Int J Oncol; 27:901–906.PubMedGoogle Scholar
  72. 72.
    Hirasawa K, Nishikawa SG, Norman KL. (2003) Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res; 63:348–353.PubMedGoogle Scholar
  73. 73.
    Bebb G, Muzik H, Alain T et al. (2005) Treatment of intermediate subviral particles overcomes resistance to reovirus induced oncolysis in mantle cell ymphoma cell lines [abstract]. In: Proceedings of the 47th Annual Meeting and Exposition of the American Society of Hematology; Blood; 2005. 106. Abstract nr. 2417.Google Scholar
  74. 74.
    Errington F, Coffey M, Hatfield P, Harrington K, Melcher AA. (2005) Potential role for reovirus in the treatment of melanoma: Targeted killing and immune stimulation [abstract]. In: Proceedings of the 96th Annual Meeting of the American Association for Cancer Research; 2005; AACR; 46. Abstract nr. 6040.Google Scholar
  75. 75.
    Zhang WE, Anders Kolb E. (2006) Reolysin, an unmodified reovirus, has significant anti-tumour activity in childhood sarcomas [abstract]. In: Proceedings of the 97th Annual Meeting of the American Association for Cancer Research; 2006; AACR; 47. Abstract nr. 4331.Google Scholar
  76. 76.
    Lane ME, Fahey JM, Besanceney C et al. (2007) In vivo synergy between oncolytic reovirus and gemicitabine in ras-mutated human HCT-116 xenografts [abstract]. In: Proceedings of the 98th Annual Meeting of the American Association for Cancer Research; 2007; AACR; 48. Abstract nr. 4812.Google Scholar
  77. 77.
    Walder S, Yu B, Lane M. (2004) The oncolytic reovirus, Reolysin, augments the anticancer effects of cytotoxic agents in vitro against the ras-mutated human colon cancer cell line HCT 116. Eur J Cancer Suppl 2:8.Google Scholar
  78. 78.
    Sei S, Yang Q, Mussio J. (2007) Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents against non-small cell lung cancer (NSCLC). European Journal of Cancer Supplements; 4:103.CrossRefGoogle Scholar
  79. 79.
    Heinemann L, Harrington KJ, Coffey M, Thompson B, Parker HS, Pandha HS. (2007) Synergistic antitumour activity of oncolytic reovirus and cisplatin in malignant melanoma [abstract]. In: The 4th international conference on oncolytic viruses as cancer therapeutics; 2007.Google Scholar
  80. 80.
    Vidal L, Twigger K, White C, Coffey M, Thompson B, De-Bono J, Pandha HS, Melcher A, Kaye S, Harrington KJ. (2005) Reovirus enhances radiation cytotoxicity in vitro and in vivo. Clinical Cancer Research; 11: 23 Suppl Abs A170.Google Scholar
  81. 81.
    Deisseroth AB, Zu Z, Claxton D. (1994) Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood; 83:3068–3076.PubMedGoogle Scholar
  82. 82.
    Thirukkumaran CM, Luider JM, Stewart DA. (2005) Biological purging of breast cancer cell lines using a replication-competent oncolytic virus in human stem cell autografts. Bone Marrow Transplant; 35:1055–1064.PubMedCrossRefGoogle Scholar
  83. 83.
    Vile R. (2007) Oncolytic virotherapy and T cells: Friends, foes or ferries? In: The 4th international conference on oncolytic viruses as cancer therapeutics; 2007.Google Scholar
  84. 84.
    Errington F, Harrington KJ, Pandha HS et al. (2006) Reovirus activates dendritic cell (DC) and promotes innate Anti-Tumour immunity. In: 1st Joint Meeting of European National Societies of Immunology; 2006.Google Scholar
  85. 85.
    Fraser S, Merrick A, Errington F, Selby P, Toogood G, Melcher A. (2007) Reovirus as a potentially immunogenic as well as cytotoxic therapy for metastatic colorectal cancer. In: Proceedings of the Society of Academic & Research Surgery conference; 2007.Google Scholar
  86. 86.
    Errington F, Coffey M, Hatfield P, Harrington K, Melcher AA. (2005) Potential role for reovirus in the treatment of melanoma: Targeted killing and immune stimulation [abstract]. In: Proceedings of the 96th Annual Meeting of the American Association for Cancer Research; 2005; AACR; 46. Abstract nr. 6040.Google Scholar
  87. 87.
    Dermody TS. (1998) Molecular mechanisms of persistent infection by reovirus. Curr Top Microbiol Immunol 212:272–276.Google Scholar
  88. 88.
    Alain T, Kim M, Johnston RN. (2006) The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro. Br J Cancer; 95:1020–1027.PubMedCrossRefGoogle Scholar
  89. 89.
    Kim M, Egan C, Alain T. (2007) Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells. Oncogene; 26:4124–4134PubMedCrossRefGoogle Scholar
  90. 90.
    Vidal L, Pandha HS, Yap TA et al. (2008) A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res; 14(21):7127–7137. PubMedCrossRefGoogle Scholar
  91. 91.
    Vidal L, Twigger K, White CL et al. (2006) Phase I trial of intratumoral administration of reovirus type 3 (Reolysin) in combination with radiation in patients with advanced malignancies. [Abstract]. In: Proceedings of the 97th annual meeting of the American Association for Cancer Research; 2006; 47. Abstract nr. 3998.Google Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Tom Baker Cancer Centre, Department of Medicine and OncologyUniversity of CalgaryCalgaryCanada
  2. 2.Department of Oncology, Tom Baker Cancer Centre, Department of Medicine and OncologyUniversity of CalgaryCalgaryCanada

Personalised recommendations